Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Schrohl, AS"'
Autor:
Holten-Andersen, Mads N., Fenger, Claus, Jørgen Nielsen, Hans, Schrohl Rasmussen, Anne-Sofie, Jarle Christensen, Ib, Brünner, Nils, Kronborg, Ole
Publikováno v:
In European Journal of Cancer 2004 40(14):2159-2164
Publikováno v:
BMC Cancer, Vol 9, Iss 1, p 322 (2009)
Abstract Background We have previously demonstrated that high tumor tissue levels of TIMP-1 are associated with no or limited clinical benefit from chemotherapy with CMF and anthracyclines in metastatic breast cancer patients. Here, we extend our inv
Externí odkaz:
https://doaj.org/article/9e204a65caf14a1ea4a405151b3e141c
Autor:
Schrohl, Anne-Sofie1, Pedersen, Hans Christian2, Jensen, Sussie Steen2, Nielsen, Signe Lykke1, Brünner, Nils1
Publikováno v:
Histopathology. Nov2011, Vol. 59 Issue 5, p975-983. 9p. 3 Color Photographs, 2 Black and White Photographs, 1 Chart, 1 Graph.
Publikováno v:
Acta Oncologica. Jun2008, Vol. 47 Issue 4, p580-590. 11p. 2 Diagrams, 1 Chart.
Autor:
Vibeke Jensen, Anne-Sofie Schrohl, Nils Brünner, Xiaohong Deng, Jan Stenvang, Louise Fogh, Ulrik Lademann, Huanming Yang
Publikováno v:
Tumor Biology. 34:1161-1170
Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been suggested as a marker of prognosis and response to treatment in breast cancer. In vitro, TIMP-1 can regulate shedding of the extracellular domain of HER2 and signalling via the Akt pathway, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c570440120a6363eea3cd36e4e443e9
https://doi.org/10.1007/s13277-013-0659-5
https://doi.org/10.1007/s13277-013-0659-5
Autor:
Nils Brünner, Anne-Sofie Schrohl, Yves Pommier, Petra Hamerlik, Magnus Stougaard, John A. Foekens, Birgitta R. Knudsen, Signe Lykke Nielsen, José M.A. Moreira, Marcel Smid, Kristina Aluzaite, Stine Ninel Hansen, John W.M. Martens, Madhavsai K. Gajjar, Julie B. Noer, Britt Damsgaard, Haatisha Jandu, Louise Fogh, Khoa Nguyen Do, Jan Stenvang, Joanna Proszek, Sebastian Wingaard Thrane
Publikováno v:
Jandu, H, Aluzaite, K, Fogh, L, Thrane, S W, Noer, J B, Proszek, J, Do, K N, Hansen, S N, Damsgaard, B, Nielsen, S L, Stougaard, M, Knudsen, B R, Moreira, J, Hamerlik, P, Gajjar, M, Smid, M, Martens, J, Foekens, J, Pommier, Y, Brünner, N, Schrohl, A-S & Stenvang, J 2016, ' Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines ', BMC Cancer, vol. 16, no. 1, 34 . https://doi.org/10.1186/s12885-016-2071-1
BMC Cancer
Jandu, H, Aluzaite, K, Fogh, L, Thrane, S W, Noer, J B, Proszek, J, Nguyen Do, K, Hansen, S N, Damsgaard, B, Nielsen, S L, Stougaard, M, Knudsen, B R, Moreira, J, Hamerlik, P, Gajjar, M, Smid, M, Martens, J, Foekens, J, Pommier, Y, Brunner, N, Schrohl, A-S & Stenvang, J 2016, ' Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines ', B M C Cancer, vol. 16, no. 1, 34 . https://doi.org/10.1186/s12885-016-2071-1
BMC Cancer, 16:34. BioMed Central Ltd.
BMC Cancer
Jandu, H, Aluzaite, K, Fogh, L, Thrane, S W, Noer, J B, Proszek, J, Nguyen Do, K, Hansen, S N, Damsgaard, B, Nielsen, S L, Stougaard, M, Knudsen, B R, Moreira, J, Hamerlik, P, Gajjar, M, Smid, M, Martens, J, Foekens, J, Pommier, Y, Brunner, N, Schrohl, A-S & Stenvang, J 2016, ' Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines ', B M C Cancer, vol. 16, no. 1, 34 . https://doi.org/10.1186/s12885-016-2071-1
BMC Cancer, 16:34. BioMed Central Ltd.
Background Studies in taxane and/or anthracycline refractory metastatic breast cancer (mBC) patients have shown approximately 30 % response rates to irinotecan. Hence, a significant number of patients will experience irinotecan-induced side effects w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e5e4ebd0162eaf53b4b940488188f58
https://doi.org/10.1186/s12885-016-2071-1
https://doi.org/10.1186/s12885-016-2071-1
Autor:
Haatisha Jandu, Aluzaite, Kristina, Fogh, Louise, Thrane, Sebastian, Noer, Julie, Proszek, Joanna, Do, Khoa, Hansen, Stine, Damsgaard, Britt, Nielsen, Signe, Stougaard, Magnus, Knudsen, Birgitta, Moreira, José, Hamerlik, Petra, Madhavsai Gajjar, Smid, Marcel, Martens, John, Foekens, John, Pommier, Yves, Brünner, Nils, Anne-Sofie Schrohl, Stenvang, Jan
This file contains the following: Table S1: a table with FISH data of TOP1/CEN-20 and TOP2A/CEN-17, TOP1/CEN-20 analyses of 52 human breast cancer cell lines. Figure S1: correlations between TOP1 copynumbers from FISH and SNP analyses, and correlatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e392f9d3c9b2c61d1da24f6b1c08d89
Autor:
Signe Lykke Nielsen, Hans Christian Pedersen, Sussie Steen Jensen, Nils Brünner, Anne-Sofie Schrohl
Publikováno v:
Histopathology
Schrohl A-S, Pedersen H C, Jensen S S, Nielsen S L & Brunner N (2011) Histopathology59, 975–983 Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies Aims: The availability of specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e05c7b80f7a972074a79ced98e70dce
https://doi.org/10.1111/j.1365-2559.2011.04034.x
https://doi.org/10.1111/j.1365-2559.2011.04034.x
Autor:
Boye Schnack Nielsen, A Schrohl, Susanne Møller, Sidse Ørnbjerg Würtz, Nils Brünner, Henning T. Mouridsen
Publikováno v:
Cancer Research. 70:P4-07
Background: Plasma levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) have been reported as predictors of poor prognosis. Indeed, in a previous study of 519 primary breast cancer patients we reported that high levels of TIMP-1 were associate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b27cc276a2be30d89e7b3f845307f742
https://doi.org/10.1158/0008-5472.sabcs10-p4-07-04
https://doi.org/10.1158/0008-5472.sabcs10-p4-07-04
Autor:
Christoph Thomssen, Klaus Pantel, Anne-Sofie Schrohl, Volkmar Mueller, Nils Bruenner, Ib Jarle Christensen
Publikováno v:
Tumor Biology. 29:181-187
Objective: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::480bb8652db8c2b01127e7a7d54465b5
https://doi.org/10.1159/000146863
https://doi.org/10.1159/000146863